Propanc Biopharma, Inc. filings document a development-stage biopharmaceutical issuer centered on PRP, a proenzyme formulation using trypsinogen and chymotrypsinogen for recurrent and metastatic cancer programs. Registration statements and amendments disclose the company’s business, financial statements, clinical-development plans, risk factors, offering terms, and capital needs.
Material-event reports cover financing and governance actions, including Series C Preferred Stock, related warrants, amendments to charter documents, board changes, and Nasdaq listing-compliance notices. The filing record also details capitalization, preferred-stock rights and conversion mechanics, unregistered equity sales, and public-company reporting obligations tied to Propanc’s oncology development strategy.
Propanc Biopharma, Inc. has filed a resale registration statement covering up to 15,000,000 shares of common stock for a single selling stockholder, Hexstone Capital LLC. These shares are issuable upon conversion of Series C Preferred Stock already issued or issuable under a warrant.
The company will not receive proceeds from any resale of these shares, only from potential future cash exercises of the warrant. Propanc is a development‑stage oncology company focused on its lead candidate PRP for pancreatic, ovarian and colorectal cancers, with no revenue, large accumulated losses, and substantial doubt about its ability to continue as a going concern absent new capital.
Propanc Biopharma, Inc. approved the issuance of specific restricted common shares to officers, directors and service providers and authorized a reverse stock split between 1-for-10 and 1-for-30.
The Board approved detailed New Stock Issuances on March 16, 2026, including 7,000,000 shares to James Nathanielsz and multiple grants of 2,000,000–2,500,000 shares to named recipients. The Board also approved a Reverse Stock Split in a ratio between 1:10 and 1:30. As of March 16, 2026, there were 20,900,649 shares of Common Stock outstanding; the Majority Stockholder (holding 8,732 common shares and 1 Series B Preferred share) voted in favor, representing approximately 50.01% of voting power.
Propanc Biopharma, Inc. notifies shareholders that its Board and the holder of a majority of voting power approved two corporate actions by written consent: (1) the issuance of restricted Common Stock to officers, directors and service providers and (2) a reverse stock split at a ratio between 1:10 and 1:30.
The Information Statement lists specific New Stock Issuances totaling 33,000,000 shares (7,000,000 to James Nathanielsz and multiple allocations of 2,000,000 and 2,500,000 shares to others) and states there were 20,900,649 shares outstanding as of March 16, 2026. The Majority Stockholder (holding 8,732 common shares and 1 share of Series B Preferred) voted in favor, representing approximately 50.01% of the voting equity.
Propanc Biopharma, Inc. notifies shareholders that its Board and a majority stockholder approved two corporate actions by written consent on March 16, 2026: (1) issuance of a total of 33,000,000 restricted shares to officers, directors and service providers (the "New Stock Issuances"); and (2) a reverse stock split at a ratio between 1:10 and 1:30 (the "Reverse Stock Split").
The Information Statement states there were 20,900,649 shares outstanding as of March 16, 2026, and the Majority Stockholder holding 8,732 common shares plus 1 share of Series B Preferred (approximately 50.01% of voting power) consented. The Reverse Stock Split, when processed and approved by Nasdaq, would reduce outstanding shares to between approximately 2,090,065 and 696,688, with proportional adjustments to option and warrant terms.
Propanc Biopharma, Inc. registers up to 7,000,000 shares of Common Stock for resale by the selling stockholder.
The prospectus states the registered shares include conversions of 100 Initial Shares of Series C Preferred Stock and 9,900 Series C Preferred Stock issuable upon exercise of a Warrant held by Hexstone Capital LLC, and that the Company will not receive proceeds from resales by the selling stockholder. The Warrant exercise price is stated as $10,000 per Series C share; if exercised in full for cash, the Company would receive approximately $99,000,000. The Certificate of Designation includes a 4.99% beneficial ownership limitation (adjustable to 9.99% with notice). Shares outstanding are reported as 15,091,133 before and 22,091,133 after the offering, assuming sale of all registered Shares.
Propanc Biopharma reported a board change. Effective February 20, 2026, long-serving director Dr. Julian Kenyon retired from the Board of Directors to focus on his personal and family life, but he will continue to support the company as a medical advisor.
The Board filled the resulting vacancy the same day by appointing Dr. Ralf Brandt as a new director. Dr. Brandt is an experienced pharmaceutical and oncology research executive with more than thirty years in drug discovery, angiogenesis, and pre-clinical development, and has advanced over 50 compounds to clinical studies.
Propanc Biopharma, Inc. has filed an amended Form S-1 registering the resale of up to 7,000,000 shares of common stock by a single selling stockholder. These shares are issuable upon conversion of 100 outstanding shares and up to 9,900 warrant-exercisable shares of Series C Preferred Stock.
The company will not receive proceeds from the resale, but would receive cash if the Series C warrant is exercised, with potential gross proceeds of approximately $99,000,000.00. An earlier private placement generated about $1,000,000.00 in gross proceeds. Common shares outstanding were 15,091,133 as of January 26, 2026, rising to 22,091,133 if all registered shares are sold.
Propanc is a development-stage biotech focused on its lead cancer candidate PRP and discloses substantial doubts about its ability to continue as a going concern, given no revenues, large accumulated deficits and reliance on external financing. The company is a smaller reporting and controlled company, highlighting extensive risks around liquidity, dilution, volatility and speculative nature of its stock.
Propanc Biopharma, Inc. reported results for the three and six months ended December 31, 2025, reflecting continued development-stage operations with no revenue and widening losses. The company posted a net loss of $3.1 million for the quarter and $7.9 million for the six-month period, driven mainly by $8.3 million of operating expenses, largely administration and stock-based costs.
Cash improved to $561,237 at December 31, 2025 from $12,088 at June 30, 2025, primarily due to financing activities. During August 2025, the company sold 1,000,000 common shares for $4.0 million in gross proceeds (about $3.3 million net), and in November 2025 it issued 100 shares of Series C Preferred Stock and related warrants for $1,000,099 in cash.
The accumulated deficit reached $134.5 million, and management disclosed that recurring losses, negative operating cash flow of $2.9 million over six months, and limited cash resources raise substantial doubt about the company’s ability to continue as a going concern for at least twelve months. As of February 16, 2026, there were 15,859,280 common shares outstanding, highlighting recent equity issuance and dilution as key elements of the funding strategy while the lead candidate PRP remains in preclinical development.